2020
DOI: 10.5694/mja2.50471
|View full text |Cite
|
Sign up to set email alerts
|

Exploring the role of a recently licensed dengue vaccine in Australian travellers

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2020
2020

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 14 publications
0
1
0
Order By: Relevance
“…Given the increasing data supporting a hyperinflammatory state in adults with severe COVID-19 [74], clinical research trials are ongoing to evaluate the effect of IL-6 blockade on COVID-19 outcomes [75,76]. Treatment with systemic corticosteroids is not routinely recommended, given a lack of survival benefit in SARS-CoV-1, possible adverse events, and concerns for prolonging viral replication and delaying viral clearance, unless clearly required for other indications (eg, ARDS, septic shock) [77].…”
Section: Treatmentmentioning
confidence: 99%
“…Given the increasing data supporting a hyperinflammatory state in adults with severe COVID-19 [74], clinical research trials are ongoing to evaluate the effect of IL-6 blockade on COVID-19 outcomes [75,76]. Treatment with systemic corticosteroids is not routinely recommended, given a lack of survival benefit in SARS-CoV-1, possible adverse events, and concerns for prolonging viral replication and delaying viral clearance, unless clearly required for other indications (eg, ARDS, septic shock) [77].…”
Section: Treatmentmentioning
confidence: 99%